FDA orphan drug designation provides incentives including regulatory support, tax credits, fee exemptions, and seven years of ...
Afuresertib plus fulvestrant cuts progression risk in HR+/HER2– metastatic breast cancer with PI3K/AKT/PTEN alterations, with ...
New targeted therapies reshape biliary tract cancer care, highlighting FGFR2/IDH1, HER2 and KRAS options plus smarter ...
Dr Christine Bestvina discusses EGFR treatment shifts, KRAS trial data, and expanding clinical trial access for community oncologists. Lung cancer treatment has undergone a remarkable transformation ...
Revised trial procedures add intensified hematologic and cardiac monitoring to mitigate toxicities consistent with dual ...
Dr. Costa addresses community-based versus academic center care debates for complex patients requiring multiple therapy lines ...
The pivotal MajesTEC-3 trial led to FDA approval of teclistamab-daratumumab for relapsed/refractory multiple myeloma after at ...
NCCN now recognizes image-only, mammogram-derived AI as a primary risk tool, shifting risk stratification from ...
During a live event, Patrick Hagen, MD, considered the evidence for using teclistamab plus daratumumab in a patient with myeloma relapse after quadruplet induction and transplant.
Dr. Nooka provides comprehensive guidance on bispecific antibody safety management, emphasizing the predictable chronology of ...
At SGO 2026, Alison Schram, MD, highlighted first-in-class tumor suppressor reactivation and emphasized early NGS testing in ...
The FDA has granted fast track designation to OPN-6602, an investigational oral dual inhibitor of EP300 and CREB-binding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results